Conference Correspondent

As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.

The combination of the investigational drug quizartinib plus azacitidine (Vidaza) or low-dose cytarabine has substantial activity in patients with myeloid leukemias and FLT3 mutations.

At the ACCC National Oncology Conference in October 2017, Brianne Joseph, LPI, brought the audience to their feet with a compelling message for those involved in cancer care.

Immune checkpoint inhibitor therapy is a relatively recent advance in the treatment of several types of cancer and has received much media attention. As healthcare professionals gain more experience with checkpoint inhibitors, it is important for them to understand that the toxicity profiles of these drugs differ from those of chemotherapeutic agents.
The National Comprehensive Cancer Network estimates that at least 33% of patients with cancer have significant psychological distress, and many patients have some levels of distress.
Patients’ perceptions of worrisome chemotherapy-related side effects have evolved since the 1980s and 1990s, according to a recent survey of women with breast and ovarian cancers that was reported at the 2017 European Society for Medical Oncology Congress.
Central obesity increases the risk for developing cancer in postmenopausal women more than high body mass index (BMI) and fat percentage, according to a study reported at the 2017 European Society for Medical Oncology Congress.
“Our study shows that women who received modern breast radiation therapy overwhelmingly found the treatment experience far better than expected,” said Susan McCloskey, MD, MSHS, at the 2017 American Society for Radiation Oncology annual meeting.
“Increasing use of netupitant plus palonosetron would potentially help greater numbers of patients avoid chemotherapy-induced nausea and vomiting, relieving them of the more debilitating complications of anticancer therapy,” said Li Zhang, MD, at the 2017 MASCC Annual Meeting.
Patient-reported outcomes (PROs) are increasingly being incorporated into clinical trial design, which has led to advances that benefit patients.
Page 2 of 45
Results 11 - 20 of 442